BioAtla Join Forces with Context Therapeutics to Develop and Commercialize BA3362 for Cancer Treatment #bioatla #contexttherapeutics #ba3362 #cancer #pharma #collaboration #agreement #development #commercialization #nectin4 pharmashots.com/19364/bioatla-…

Bladder cancer mini-orals at #ESMO24. Terrific talks from Vadim Koshkin MD UCSF Helen Diller Family Comprehensive Cancer Ctr (addressing #FGFR3 pos dz), Tom Powles Barts Experimental Cancer Medicine Centre (role of #NECTIN4 in #EV302) & Matt Galsky Mount Sinai Health System (#disitimab/#pembrolizumab). Incredibly informative talks all around - perfectly executed!

**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors** #MonoclonalADC #Nectin4 #Solidtumor #9MW2821 #cervicalcancer #urothelialcarcinoma #esophagealcancer #breastcancer More info clic→medtourcn.com/solid-tumor/30…

Breaking Ground: The First Nectin-4 Targeted ADC Approved in China – Urothelial Carcinoma #Nectin4ADC #CancerResearch #UrothelialCarcinoma #InnovativeMedicine #ChinaPharma #EnfortumabVedotin #ADC #PD1 #PDL1 #NEctin4 More info clic→ medtourcn.com/solid-tumor/28…

Learn about NEXUS-01, our Phase 1 trial of an investigational #Nectin4 targeted ADC in advanced or metastatic #UrothelialCarcinoma or other solid tumors. Find detailed trial and enrollment info here: e.lilly/3VR2ns8 #CancerResearch #ClinicalTrials #ADCs #BladderCancer

🎥 Don't miss our conversation with Niklas Klümper, MD, on an analysis of #NECTIN4 amplification as a #biomarker for predicting response to #EV in #mUC treatment. 👀 Watch Now: buff.ly/3zGuq51

🏥 From #ASCO24, presented by DrTylerStewart and colleagues: 🔍 #NECTIN4 expression could serve as a potential biomarker for selecting patients with #advanced #UC who are likely to benefit from #EV therapy. 📚 Read More: buff.ly/3RjWHEj

Patients with metastatic #urothelialcancer and increased expression of the #NECTIN4 gene had a much better response to antibody treatment than patients with reduced gene expression, according to findings from Joshua Meeks in Journal of Clinical Oncology: news.feinberg.northwestern.edu/2024/05/24/new… #BladderCancer

Patients with metastatic #UrothelialCancer and increased expression of the #NECTIN4 gene had a much better response to antibody treatment than patients with reduced gene expression, per Journal of Clinical Oncology. spr.ly/6016eBLVM

¿Podrían los biomarcadores tipo #NECTIN4 mejorar la selección de pacientes 🧑‍🤝‍🧑que tienen #CáncerUrotelialpara para ser tratados con #EnfortumabVedotin? el 👨‍⚕️Niklas Klümper y colegas lo investigaron oncobites.tv/gunews/amplifi…

📋 A study from Niklas Klümper and colleagues sought to determine if #NECTIN4 amplifications can predict #EV response in patients with #mUC. 🧠 Find Out More: buff.ly/3UfjSjS

#AACR24 attendees - Thank you to everyone who joined us in San Diego and online! #CancerResearch Visit the Loxo@Lilly congress hub to see the research we presented at this year’s meeting: e.lilly/3vt6MY4 #ClinicalTrials #KRAS #Nectin4 #SMARCA2

At #AACR24, we’re presenting preclinical data for an anti-Nectin-4 antibody drug conjugate (ADC) with a novel topoisomerase I inhibitor payload. See the data here: e.lilly/43ERuvL #ADCs #Nectin4 #CancerResearch

#AACR24 - Learn about the EXCEED trial, a phase 1 trial investigating a #Nectin4 targeted antibody drug conjugate (ADC) in advanced or metastatic urothelial cancer and other solid tumors. Trial in progress poster: e.lilly/3IWpuKx #CancerResearch #ClinicalTrials #ADCs

We’re excited to join the #CancerResearch community in San Diego for the AACR Annual Meeting 2024! Visit us onsite at the Loxo@Lilly booth (3237) or click here to explore our #AACR24 congress hub: e.lilly/3vt6MY4 #ClinicalTrials #KRAS #Nectin4 #SMARCA2(BRM)

The EXCEED Trial | NOW ENROLLING Phase 1 trial of our investigational #Nectin4 targeted antibody drug conjugate (ADC) in recurrent, advanced or metastatic solid tumors. #CancerResearch #ClinicalTrials #ADCs Click here for detailed trial/enrollment info: e.lilly/49kkcUX

#IHC #antibody #Nectin4 #PVR #CD155 S-RMab® Nectin-4 Recombinant Rabbit mAb (SDT-277-322) Catalog Number: S0B2277 Welcome to request free samples: [email protected] Find more: en.starter-bio.com/s0b2277-s-rmab… #biotech #lifescience #CDx #IVD #cancer #pathology #Immunohistochemistry

Enfortumab Vedotin Shows Meaningful, Sustained OS Benefit in Bladder Cancer. The median OS estimates in each respective arm were 12.91 months (95% CI, 11.01-14.92) compared with 8.94 months (95% CI, 8.25-10.25). #bladdercancer, #ADCs, #nectin4, #enfortumab annalsofoncology.org/article/S0923-…

EAU Podcast #ESMO23 👉uroweb.org/education-even… 👉Benjamin Pradere interviews Tom Powles about EV302 (#Enfortumab+Pembro vs Platin based chemo) and CM901 (Ipi/Nivo) in 1st line mUC + possible next indications for EV such as neoadjuvant setting #BladderCancer #Nectin4 @uroweb